Abstract: It is intended to provide an antitumor drug having an excellent therapeutic effect, which is excellent in terms of antitumor effect and safety. There is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-TROP2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— wherein the anti-TROP2 antibody is connected to the terminal of L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(?O)— moiety with the nitrogen atom of the amino group at position 1 as a connecting position.

Abstract: A vehicle comprises a motor configured to output a power for driving; a power storage device configured to supply electric power to the motor; a main relay provided between the motor and the power storage device; a power receiving connector configured to be connectable with a power feed connector of an external charger; and a charging relay connected with the power receiving connector and connected with the power storage device via the main relay. This vehicle further comprises a control device configured to determine whether electric power from the external charger is supplied to the power receiving connector during charging of the power storage device with the electric power from the external charger in closed positions of the main relay and the charging relay and to open the main relay when it is determined that the electric power from the external charger is not supplied to the power receiving connector.

Abstract: An object is to avoid the situation in which the power cannot be turned off. A control system is provided in which the first and second control units are connected. At least one of the first and second control units include: a stop control section for, if a condition for ending a predetermined operation mode is satisfied in that operation mode, performing stop control for having the control system in a low-power-consumption state while communicating with the other control unit; and a mode control section for having a mode undefined state in which the operation mode is instable at restoration from a reset state and for allowing, if a predetermined transition condition for allowing transition into the operation mode is satisfied in the mode undefined state, transition into the operation mode whose transition condition has been satisfied.

Abstract: An automotive vehicle on which a motor for traveling, a battery configured to supply electric power to the motor, and a charging system configured to charge the battery, are installed. The automotive vehicle includes an abnormality informing unit configured to immediately inform occurrence of an abnormality regarding the charging system when the abnormality is detected, on a condition that the abnormality is a first abnormality that affects traveling, and inform occurrence of an abnormality when a next trip is started, on a condition that the abnormality is a second abnormality that does not affect traveling.

Abstract: It is intended to provide an antitumor drug having an excellent therapeutic effect, which is excellent in terms of antitumor effect and safety. There is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-TROP2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— wherein the anti-TROP2 antibody is connected to the terminal of L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(?O)— moiety with the nitrogen atom of the amino group at position 1 as a connecting position.

Abstract: It is intended to provide an antitumor drug having an excellent therapeutic effect, which is excellent in terms of antitumor effect and safety. There is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-TROP2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— wherein the anti-TROP2 antibody is connected to the terminal of L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(?O)— moiety with the nitrogen atom of the amino group at position 1 as a connecting position.

Abstract: An object is to avoid the situation in which the power cannot be turned off. A control system is provided in which the first and second control units are connected. At least one of the first and second control units include: a stop control section for, if a condition for ending a predetermined operation mode is satisfied in that operation mode, performing stop control for having the control system in a low-power-consumption state while communicating with the other control unit; and a mode control section for having a mode undefined state in which the operation mode is instable at restoration from a reset state and for allowing, if a predetermined transition condition for allowing transition into the operation mode is satisfied in the mode undefined state, transition into the operation mode whose transition condition has been satisfied.

Abstract: The present invention, the objects of which are to find out a gene encoding a protein having functions equivalent to those of G-protein-coupled receptor (GPCR) and the protein, and to provide a method for identifying a compound that regulates functions and/or expression of the protein, and to provide a useful mean for preventing and/or treating diseases related to the gene and the protein, provides a DNA comprising base sequence described in SEQ ID NO: 1 or complementary strand thereof, complementary strand of the DNA, a protein encoded by the DNA, a vector containing the DNA, a transformant containing the vector, an antibody against the protein, a method for identifying a compound that regulates functions and/or expression of the protein using aforementioned members, an agent for improving and a method for improving depression state, a pharmaceutical composition, and a reagent kit.

Abstract: DNA encoding a cholecystokinin octapeptide sulfated form (CCK-8S) G-protein coupled receptor, a complementary strand thereof, a vector containing the DNA, a transformant containing the vector, a pharmaceutical composition, and a reagent kit are provided. Such DNA and constructs are useful in identifying a compound that inhibits or promotes a function of the protein and/or expression of a DNA encoding the protein. Such DNA and constructs are also useful for identifying an anti-depressant drug or a compound that has an anti-depressant action.

Abstract: There are provided a method for identifying a compound having an anti-anxiety effect, an inhibitor of a function of a protein having a function as a G-protein coupled receptor, characterized by finding the protein and a gene encoding the protein and using at least one of a DNA represented by the nucleotide sequence of this gene or a complementary strand thereof, a homologue of the DNA, a protein encoded by the DNA, and a cell expressing the protein encoded by the DNA, an agent and a method for improving an anxiety condition, a method and an agent for prophylactic and/or therapeutic treatment of an anxiety disorder, and a measurement method for diagnosis and a diagnostic method of an anxiety disorder.

Abstract: The present invention, the objects of which are to find out a gene encoding a protein having functions equivalent to those of G-protein-coupled receptor (GPCR) and the protein, and to provide a method for identifying a compound that regulates functions and/or expression of the protein, and to provide a useful mean for preventing and/or treating diseases related to the gene and the protein, provides a DNA comprising base sequence described in SEQ ID NO: 1 or complementary strand thereof, complementary strand of the DNA, a protein encoded by the DNA, a vector containing the DNA, a transformant containing the vector, an antibody against the protein, a method for identifying a compound that regulates functions and/or expression of the protein using aforementioned members, an agent for improving and a method for improving depression state, a pharmaceutical composition, and a reagent kit.

Abstract: Methods of providing a protein having a function as a G-protein coupled receptor and methods of identifying a compound that inhibits or promotes a function of the protein and/or expression of a DNA encoding the protein are provided. Methods for identifying an anti-depressant drug or a compound That has an anti-depressant action and methods for diagnosing depression are also provided.

Abstract: The present invention, the objects of which are to find out a gene encoding a protein having functions equivalent to those of G-protein-coupled receptor (GPCR) and the protein, and to provide a method for identifying a compound that regulates functions and/or expression of the protein, and to provide a useful mean for preventing and/or treating diseases related to the gene and the protein, provides a DNA comprising base sequence described in SEQ ID NO: 1 or complementary strand thereof, complementary strand of the DNA, a protein encoded by the DNA, a vector containing the DNA, a transformant containing the vector, an antibody against the protein, a method for identifying a compound that regulates functions and/or expression of the protein using aforementioned members, an agent for improving and a method for improving depression state, a pharmaceutical composition, and a reagent kit.